comparison of glp 1 agonists Comparing Ozempic, Wegovy and Other GLP-1 Drugs PDB-101: Molecule of the Month:
Description
Cell Stress 2 , 246252 (2018)
The LEADER-6 study shown substantial cardiovascular advantages of liraglutide in high-risk patients, while SUSTAIN-6 revealed a significant decrease in cardiovascular event-related mortality with subcutaneous semaglutide (Verma et al
Jrgensen, M
95% CI, 0.78~0.89) [22]
The FDA has received reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide products
Furthermore, early safety trials that included kidney outcomes as secondary endpoints hinted at potential renal benefits associated with these medication classes
